Demographic and clinical characteristics of participating patients (n=102) at the time of the observed consultations (‘Observed’) and for consultations reviewed in their electronic health record (‘Records’)
| CD | UC/IBD-U | Total | ||||
| Observed, n=50 | Records, n=484 | Observed, n=52 | Records, n=425 | Observed, n=102 | Records, n=909 | |
| Patient demographics | ||||||
| Gender | ||||||
| Male, n (%) | 24 (48) | 25 (48) | 49 (48) | |||
| Female, n (%) | 26 (52) | 27 (52) | 53 (52) | |||
| Age, mean (range), years | 47 (24–75) | 45 (21–75) | 49 (18–84) | 50 (18–84) | 48 (18–84) | 47 (18–84) |
| Clinical characteristics, n (%) | ||||||
| Montreal classification | ||||||
| Location/extent | L1: 21 (42) | L1: 217 (45) | E1: 13 (25) | E1: 86 (20) | N/A | N/A |
| L2: 10 (20) | L2: 86 (18) | E2: 21 (40) | E2: 185 (44) | |||
| L3: 19 (38) | L3: 181 (37) | E3: 18 (35) | E3: 154 (36) | |||
| +L4: 2 (4) | +L4: 22 (4.5) | |||||
| Behaviour | B1: 24 (48) | B1: 226 (47) | ||||
| B2: 12 (24) | B2: 123 (25) | |||||
| B3: 10 (20) | B3: 97 (20) | |||||
| B2/B3: 4 (8) | B2/B3: 38 (8) | |||||
| Perianal involvement | 12 (24) | 92 (19) | N/A | N/A | ||
| Disease duration, mean (range) | 15 (1–48) | 14 (0–48) | 10 (0–48) | 10 (0–48) | 13 (0–48) | 12 (0–48) |
| Previous IBD surgery | 32 (64) | 300 (62) | 4 (8) | 27 (6) | 36 (35) | 324 (36) |
| Stoma present | 12 (24) | 100 (21) | 4 (8) | 27 (6) | 16 (16) | 127 (14) |
| Extra-intestinal manifestations | 13 (26) | 126 (26) | 8 (15) | 62 (15) | 21 (21) | 188 (21) |
| Current medical therapy | ||||||
| No regular IBD medication | 10 (20) | 94 (19) | 9 (17) | 49 (12) | 19 (19) | 143 (16) |
| 5-ASA only | 3 (6) | 33 (7) | 25 (48) | 228 (54) | 28 (28) | 261 (29) |
| Corticosteroids | 4 (8) | 48 (10) | 10 (19) | 61 (14) | 14 (14) | 109 (12) |
| Immunomodulators | 24 (48) | 240 (50) | 8 (15) | 84 (20) | 32 (31) | 313 (34) |
| Anti-TNF therapies | 19 (38) | 154 (32) | 5 (10) | 47 (11) | 24 (24) | 201 (22) |
| Other biologic therapies | 3 (6) | 24 (5) | 1 (2) | 6 (1) | 4 (4) | 30 (3) |
5-ASA, 5-aminosalicyclic acid; CD, Crohn’s disease; IBD, inflammatory bowel disease; IBD-U, inflammatory bowel disease-unclassified; TNF, Tumour necrosis factor alpha; UC, ulcerative colitis.